Generic Version of Azopt Now Available
Brinzolamide ophthalmic suspension 1% is indicated for elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Brinzolamide ophthalmic suspension 1% is indicated for elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Research shows patients with glaucoma are likely to encounter conflicting opinions on marijuana’s role in glaucoma therapy, especially from dispensaries.
Researchers investigated an association between blood pressure medications and glaucoma.
Study shows reductions in intraocular pressures and antiglaucoma medication use.
A growing body of research shows SLT for first-line glaucoma therapy works as well as drops — so why aren’t clinician’s embracing it?
This slideshow shows drug information for Durysta. Click here for the complete Durysta monograph.
Delayed or canceled appointments during lockdown causing the greatest concern.
The Food and Drug Administration (FDA) has approved Durysta (bimatoprost implant; Allergan) for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
This article is part of MPR’s coverage of the American Academy of Ophthalmology 2019 Meeting, taking place in San Francisco, CA. Our staff will report on medical research related to eye disorders, conducted by experts in the field. Check back regularly for more news from AAO 2019. SAN FRANCISCO – Sepetaprost 0.002% was found to…
Latanoprostene bunod showed greater reduction in intraocular pressure (IOP) after 3 months compared to other treatments for open-angle glaucoma and ocular hypertension.